1. Home
  2. GANX vs BEDU Comparison

GANX vs BEDU Comparison

Compare GANX & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • BEDU
  • Stock Information
  • Founded
  • GANX 2017
  • BEDU 1994
  • Country
  • GANX United States
  • BEDU United Kingdom
  • Employees
  • GANX N/A
  • BEDU 2193
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • BEDU Other Consumer Services
  • Sector
  • GANX Health Care
  • BEDU Real Estate
  • Exchange
  • GANX Nasdaq
  • BEDU Nasdaq
  • Market Cap
  • GANX 45.8M
  • BEDU 47.7M
  • IPO Year
  • GANX 2021
  • BEDU 2017
  • Fundamental
  • Price
  • GANX $1.94
  • BEDU $1.51
  • Analyst Decision
  • GANX Strong Buy
  • BEDU
  • Analyst Count
  • GANX 5
  • BEDU 0
  • Target Price
  • GANX $8.20
  • BEDU N/A
  • AVG Volume (30 Days)
  • GANX 310.3K
  • BEDU 13.9K
  • Earning Date
  • GANX 05-20-2025
  • BEDU 04-28-2025
  • Dividend Yield
  • GANX N/A
  • BEDU N/A
  • EPS Growth
  • GANX N/A
  • BEDU N/A
  • EPS
  • GANX N/A
  • BEDU N/A
  • Revenue
  • GANX N/A
  • BEDU $224,321,752.00
  • Revenue This Year
  • GANX N/A
  • BEDU N/A
  • Revenue Next Year
  • GANX N/A
  • BEDU N/A
  • P/E Ratio
  • GANX N/A
  • BEDU N/A
  • Revenue Growth
  • GANX N/A
  • BEDU N/A
  • 52 Week Low
  • GANX $0.89
  • BEDU $1.35
  • 52 Week High
  • GANX $3.19
  • BEDU $2.42
  • Technical
  • Relative Strength Index (RSI)
  • GANX 50.18
  • BEDU 42.49
  • Support Level
  • GANX $1.85
  • BEDU $1.40
  • Resistance Level
  • GANX $2.07
  • BEDU $1.94
  • Average True Range (ATR)
  • GANX 0.15
  • BEDU 0.11
  • MACD
  • GANX 0.02
  • BEDU -0.00
  • Stochastic Oscillator
  • GANX 40.00
  • BEDU 20.41

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About BEDU Bright Scholar Education Holdings Limited each representing four

Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.

Share on Social Networks: